Great Point Partners
Great Point Partners reported 41 stocks worth $381M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are VERA (6.8%), VOR (5.6%) and AMLX (5.3%). Compared with Q2 2026, the fund opened new positions in IONS, GMAB and BLTE, added to VERA, DFTX and LBRX, trimmed VOR, SGMT and SLGL and sold out of ALMS, IMMX and SLN.
Latest filing: what Great Point Partners did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() VERA Vera Therapeutics Inc | $26.1M | 6.8% | 809K | +208K (+35%) | 3 of 8 | |
| 2 | ![]() VOR Vor Biopharma Inc Com New | $21.5M | 5.6% | 1.1M | −573K (−34%) | 4 of 8 | |
| 3 | ![]() AMLX Amylyx Pharmaceuticals Inc | $20.4M | 5.3% | 700K | No change | 7 of 8 | |
| 4 | ![]() SGMT Sagimet Biosciences Inc | $19.4M | 5.1% | 2M | −68K (−3%) | 2 of 8 | |
| 5 | ![]() DFTX Definium Therapeutics Inc | $19.4M | 5.1% | 509K | +84K (+20%) | 2 of 8 | |
| 6 | ![]() IONS Ionis Pharmaceuticals Inc | $18.8M | 4.9% | 420K | New position | 5 of 8 | |
| 7 | ![]() GMAB Genmab A/s | $18.7M | 4.9% | 525K | New position | 1 of 8 | |
| 8 | ![]() SLGL Sol Gel Technologies | $17.8M | 4.7% | 239K | −35K (−13%) | 3 of 8 | |
| 9 | ![]() ZURA Zura Bio Ltd | $17M | 4.5% | 4.1M | −139K (−3%) | 8 of 8 | |
| 10 | ![]() LBRX LB Pharmaceuticals Inc | $15.8M | 4.1% | 410K | +93K (+29%) | 3 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Options
valued at the underlying sharesReported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Great Point Partners 13F FAQ
What does Great Point Partners own?
Great Point Partners reported 41 stocks worth $381M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are VERA (6.8%), VOR (5.6%) and AMLX (5.3%). The table above lists every position in the filing (the top 10 without an account).
What did Great Point Partners buy and sell in Q3 2026?
Compared with Q2 2026: 9 new positions, 4 added to, 11 trimmed and 5 sold out. New positions include IONS, GMAB and BLTE. It sold all of ALMS, IMMX and SLN.
When will Great Point Partners file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Great Point Partners's portfolio worth?
The Q3 2026 filing reports $381M in US stocks ($418M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.

























